Identification of steroid derivatives that function as potent antiandrogens

Hiroshi Miyamoto, Padma Marwah, Ashok Marwah, Zhiming Yang, Chin Ying Chung, Saleh Altuwaijri, Chawnshang Chang, Henry Lardy

Research output: Contribution to journalArticle

Abstract

We have hypothesized that some steroid derivatives bind to the androgen receptor (AR) with very low androgenic activity and therefore potentially function as better AR antagonists than clinically used antiandrogens, such as flutamide. Indeed, we previously found such a compound, 3β-acetoxyandrosta- 1,5-diene-17-one ethylene ketal (ADEK), with some estrogenic activity. Here we report the identification of 2 additional steroid derivatives, 3β-hydroxyandrosta-5,16-diene (HAD) and androsta-1,4-diene-3,17-dione-17- ethylene ketal (OAK), as new potent antiandrogens. Like ADEK, HAD and OAK could interrupt androgen binding to the AR and suppress both dihydrotestosterone- and androstenediol-induced transactivations of wild-type and mutant ARs in prostate cancer cells. These 2 compounds also inhibited prostate-specific antigen expression in LNCaP as well as growth of different AR-positive prostate cancer cell lines stimulated by androgen. Significantly, HAD and OAK had only marginal agonist effects, as compared to hydroxyflutamide. More importantly, in contrast to ADEK, OAK was shown to possess marginal estrogenic activity. These results strengthen our hypothesis and suggest that selective steroid derivatives could be potent antiandrogenic drugs with less unfavorable effects for the treatment of prostate cancer.

Original languageEnglish (US)
Pages (from-to)866-872
Number of pages7
JournalInternational Journal of Cancer
Volume117
Issue number5
DOIs
StatePublished - Dec 10 2005
Externally publishedYes

Fingerprint

Androgen Antagonists
Androgen Receptors
Steroids
Prostatic Neoplasms
Androgens
Androstenediol
Androgen Receptor Antagonists
Flutamide
Dihydrotestosterone
Prostate-Specific Antigen
Transcriptional Activation
Cell Line
ethylene
Growth
Pharmaceutical Preparations

Keywords

  • Androgen receptor, antiandrogens
  • Antiandrogen withdrawal syndrome
  • Prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Miyamoto, H., Marwah, P., Marwah, A., Yang, Z., Chung, C. Y., Altuwaijri, S., ... Lardy, H. (2005). Identification of steroid derivatives that function as potent antiandrogens. International Journal of Cancer, 117(5), 866-872. https://doi.org/10.1002/ijc.21217

Identification of steroid derivatives that function as potent antiandrogens. / Miyamoto, Hiroshi; Marwah, Padma; Marwah, Ashok; Yang, Zhiming; Chung, Chin Ying; Altuwaijri, Saleh; Chang, Chawnshang; Lardy, Henry.

In: International Journal of Cancer, Vol. 117, No. 5, 10.12.2005, p. 866-872.

Research output: Contribution to journalArticle

Miyamoto, H, Marwah, P, Marwah, A, Yang, Z, Chung, CY, Altuwaijri, S, Chang, C & Lardy, H 2005, 'Identification of steroid derivatives that function as potent antiandrogens', International Journal of Cancer, vol. 117, no. 5, pp. 866-872. https://doi.org/10.1002/ijc.21217
Miyamoto H, Marwah P, Marwah A, Yang Z, Chung CY, Altuwaijri S et al. Identification of steroid derivatives that function as potent antiandrogens. International Journal of Cancer. 2005 Dec 10;117(5):866-872. https://doi.org/10.1002/ijc.21217
Miyamoto, Hiroshi ; Marwah, Padma ; Marwah, Ashok ; Yang, Zhiming ; Chung, Chin Ying ; Altuwaijri, Saleh ; Chang, Chawnshang ; Lardy, Henry. / Identification of steroid derivatives that function as potent antiandrogens. In: International Journal of Cancer. 2005 ; Vol. 117, No. 5. pp. 866-872.
@article{ef6c9f64c5474f58a84542a3d35fdb82,
title = "Identification of steroid derivatives that function as potent antiandrogens",
abstract = "We have hypothesized that some steroid derivatives bind to the androgen receptor (AR) with very low androgenic activity and therefore potentially function as better AR antagonists than clinically used antiandrogens, such as flutamide. Indeed, we previously found such a compound, 3β-acetoxyandrosta- 1,5-diene-17-one ethylene ketal (ADEK), with some estrogenic activity. Here we report the identification of 2 additional steroid derivatives, 3β-hydroxyandrosta-5,16-diene (HAD) and androsta-1,4-diene-3,17-dione-17- ethylene ketal (OAK), as new potent antiandrogens. Like ADEK, HAD and OAK could interrupt androgen binding to the AR and suppress both dihydrotestosterone- and androstenediol-induced transactivations of wild-type and mutant ARs in prostate cancer cells. These 2 compounds also inhibited prostate-specific antigen expression in LNCaP as well as growth of different AR-positive prostate cancer cell lines stimulated by androgen. Significantly, HAD and OAK had only marginal agonist effects, as compared to hydroxyflutamide. More importantly, in contrast to ADEK, OAK was shown to possess marginal estrogenic activity. These results strengthen our hypothesis and suggest that selective steroid derivatives could be potent antiandrogenic drugs with less unfavorable effects for the treatment of prostate cancer.",
keywords = "Androgen receptor, antiandrogens, Antiandrogen withdrawal syndrome, Prostate cancer",
author = "Hiroshi Miyamoto and Padma Marwah and Ashok Marwah and Zhiming Yang and Chung, {Chin Ying} and Saleh Altuwaijri and Chawnshang Chang and Henry Lardy",
year = "2005",
month = "12",
day = "10",
doi = "10.1002/ijc.21217",
language = "English (US)",
volume = "117",
pages = "866--872",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Identification of steroid derivatives that function as potent antiandrogens

AU - Miyamoto, Hiroshi

AU - Marwah, Padma

AU - Marwah, Ashok

AU - Yang, Zhiming

AU - Chung, Chin Ying

AU - Altuwaijri, Saleh

AU - Chang, Chawnshang

AU - Lardy, Henry

PY - 2005/12/10

Y1 - 2005/12/10

N2 - We have hypothesized that some steroid derivatives bind to the androgen receptor (AR) with very low androgenic activity and therefore potentially function as better AR antagonists than clinically used antiandrogens, such as flutamide. Indeed, we previously found such a compound, 3β-acetoxyandrosta- 1,5-diene-17-one ethylene ketal (ADEK), with some estrogenic activity. Here we report the identification of 2 additional steroid derivatives, 3β-hydroxyandrosta-5,16-diene (HAD) and androsta-1,4-diene-3,17-dione-17- ethylene ketal (OAK), as new potent antiandrogens. Like ADEK, HAD and OAK could interrupt androgen binding to the AR and suppress both dihydrotestosterone- and androstenediol-induced transactivations of wild-type and mutant ARs in prostate cancer cells. These 2 compounds also inhibited prostate-specific antigen expression in LNCaP as well as growth of different AR-positive prostate cancer cell lines stimulated by androgen. Significantly, HAD and OAK had only marginal agonist effects, as compared to hydroxyflutamide. More importantly, in contrast to ADEK, OAK was shown to possess marginal estrogenic activity. These results strengthen our hypothesis and suggest that selective steroid derivatives could be potent antiandrogenic drugs with less unfavorable effects for the treatment of prostate cancer.

AB - We have hypothesized that some steroid derivatives bind to the androgen receptor (AR) with very low androgenic activity and therefore potentially function as better AR antagonists than clinically used antiandrogens, such as flutamide. Indeed, we previously found such a compound, 3β-acetoxyandrosta- 1,5-diene-17-one ethylene ketal (ADEK), with some estrogenic activity. Here we report the identification of 2 additional steroid derivatives, 3β-hydroxyandrosta-5,16-diene (HAD) and androsta-1,4-diene-3,17-dione-17- ethylene ketal (OAK), as new potent antiandrogens. Like ADEK, HAD and OAK could interrupt androgen binding to the AR and suppress both dihydrotestosterone- and androstenediol-induced transactivations of wild-type and mutant ARs in prostate cancer cells. These 2 compounds also inhibited prostate-specific antigen expression in LNCaP as well as growth of different AR-positive prostate cancer cell lines stimulated by androgen. Significantly, HAD and OAK had only marginal agonist effects, as compared to hydroxyflutamide. More importantly, in contrast to ADEK, OAK was shown to possess marginal estrogenic activity. These results strengthen our hypothesis and suggest that selective steroid derivatives could be potent antiandrogenic drugs with less unfavorable effects for the treatment of prostate cancer.

KW - Androgen receptor, antiandrogens

KW - Antiandrogen withdrawal syndrome

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=27744443765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744443765&partnerID=8YFLogxK

U2 - 10.1002/ijc.21217

DO - 10.1002/ijc.21217

M3 - Article

C2 - 15981214

AN - SCOPUS:27744443765

VL - 117

SP - 866

EP - 872

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -